Back to search

Article

Strategies for DPYD Testing Prior to Fluoropyrimidine Chemotherapy in the United States

2024-05-14

Abstract excerpt

<title>Abstract</title> <p>Purpose Patients with dihydropyrimidine dehydrogenase (DPD) deficiency are at high risk for severe and fatal toxicity from fluoropyrimidine (FP) chemotherapy. Pre-treatment <italic>DPYD</italic> testing is standard of care in many countries, but not the United States (US). This survey assessed pre-treatment <italic>DPYD</italic> testing approaches in the US to identify best practices f...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
745b6307-6776-507d-90dc-13eca327f7cd
DOI
10.21203/rs.3.rs-4207186/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Strategies for DPYD Testing Prior to Fluoropyrimidine Chemotherapy in the United StatesDOI 10.21203/rs.3.rs-4207186/v1
A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical PracticeSemantic proximity
Addressing barriers to increased adoption of DPYD genotyping at a large multisite cancer center.Semantic proximity
Importance of and Strategies for Implementing DPYD Testing to Prevent Severe Fluoropyrimidine Chemotherapy Toxicity in Health Care Systems.Semantic proximity
Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementationSemantic proximity
Design and Implementation of an Opt-Out, End-to-End, Preemptive DPYD Testing Program for Patients Planned for a Systemic FluoropyrimidineSemantic proximity
Clinical Implementation of DPYD Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in SwitzerlandSemantic proximity
DPYD genotyping and dihydropyrimidine dehydrogenase (DPD) phenotyping in clinical oncology. A clinically focused minireview.Semantic proximity
Confirmatory DPYD Testing in Patients Receiving Fluoropyrimidines Who are Suspected DPYD Variant Carriers Based on a Genetic Data Repository.Semantic proximity
All You Need to Know About DPYD Genetic Testing for Patients Treated With Fluorouracil and Capecitabine: A Practitioner-Friendly GuideSemantic proximity
Real‐world implementation of DPYD and UGT1A1 pharmacogenetic testing in a community‐based cancer centerSemantic proximity
Real-World Impact of an In-House Dihydropyrimidine Dehydrogenase (DPYD) Genotype Test on Fluoropyrimidine Dosing, Toxicities, and Hospitalizations at a Multisite Cancer Center.Semantic proximity
Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD VariantsSemantic proximity
Select a neighboring publication to make it the new centre.